Today: 29 June 2026
Browse Category

Stock Market 21 January 2026

ASX slides as Trump Greenland tariff threat sparks ‘sell America’ trade — gold hits record

ASX slides as Trump Greenland tariff threat sparks ‘sell America’ trade — gold hits record

The S&P/ASX 200 fell 0.4% by mid-morning Wednesday, led by declines in tech and banks, while miners rose on record gold prices near $4,762 an ounce. U.S. President Trump threatened new tariffs on eight European countries after their troops arrived in Greenland, escalating trade tensions. Lynas Rare Earths jumped on a 43% revenue surge. Rio Tinto reported record quarterly iron ore shipments.
21 January 2026
····
Morgan Stanley stock drops 3.7% after-hours as rate-cap deadline and tariff jitters hit banks

Morgan Stanley stock drops 3.7% after-hours as rate-cap deadline and tariff jitters hit banks

Morgan Stanley shares fell 3.7% to $182.10 Tuesday, tracking a broader drop in U.S. bank stocks after the Trump administration threatened a 10% cap on credit-card interest rates. Trading volume doubled its 50-day average. The S&P 500 lost 2.06%. Morgan Stanley’s board declared a $1.00 quarterly dividend, payable Feb. 13 to shareholders of record Jan. 30.
21 January 2026
··
Bank of America stock slips after $1B employee stock award as credit-card cap deadline bites

Bank of America stock slips after $1B employee stock award as credit-card cap deadline bites

Bank of America shares fell 1.64% to $52.10 Tuesday, then held steady after hours. The bank announced a $1 billion employee stock grant, totaling nearly 19 million shares. Investors weighed the move against uncertainty over a possible 10% federal cap on credit-card interest rates. CEO Brian Moynihan sold and repurchased about 17,900 shares last week, according to SEC filings.
21 January 2026
···
Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals shares soared over 167% to $21.41 in after-hours trading Tuesday after reporting positive placebo-controlled trial results for its experimental eczema pill. The company launched a $150 million underwritten stock and warrant offering following the data release. Analysts raised price targets. About 84 million shares changed hands.
21 January 2026
··
Lumentum stock jumps 10% as Aletheia lifts target to $500 ahead of Feb. 3 earnings

Lumentum stock jumps 10% as Aletheia lifts target to $500 ahead of Feb. 3 earnings

Lumentum shares rose about 10% Tuesday, closing at $356.83 and holding steady after hours. Aletheia Capital’s Skye Chen raised his price target to $500, citing stronger demand for high-speed data-center lasers. Lumentum reports fiscal Q2 results Feb. 3 after the market closes. The company will also present new laser platforms at SPIE Photonics West this week.
21 January 2026
··
Applied Materials stock price dips despite Needham’s big target hike — here’s what traders watch next

Applied Materials stock price dips despite Needham’s big target hike — here’s what traders watch next

Applied Materials fell 2.7% to $318.23 Tuesday, mirroring a sharp drop in semiconductor stocks and the S&P 500. The decline came despite Needham raising its price target to $390, citing stronger demand. Shares traded between $314.58 and $324.35 on volume of 9.4 million. Investors await earnings from ASML and KLA next week, with Applied’s own report due Feb. 12.
21 January 2026
·
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

Rapt Therapeutics shares surged 64% to $57.57 in after-hours trading after GSK agreed to acquire the company for $58 a share in cash, valuing Rapt at about $2.2 billion. The deal centers on ozureprubart, a long-acting anti-IgE antibody. GSK plans to launch a tender offer within 10 business days. Closing depends on a majority of Rapt shares being tendered and U.S. antitrust clearance.
21 January 2026
···
Goldman Sachs stock drops after-hours as credit-card cap deadline hits banks; Qatar $25B tie-up in focus

Goldman Sachs stock drops after-hours as credit-card cap deadline hits banks; Qatar $25B tie-up in focus

Goldman Sachs shares fell 1.9% to $943.37 in after-hours trading Tuesday as investors awaited a White House decision on capping credit card interest rates. Bank stocks broadly declined, with JPMorgan down 3.1% and Citigroup off 4.4%. Goldman also announced a new deal with the Qatar Investment Authority to raise up to $25 billion for managed funds and co-investments. RBC Capital raised its price target on Goldman to $1,030.
21 January 2026
····
Coinbase stock drops after hours as bitcoin slides; Armstrong keeps crypto bill push alive in Davos

Coinbase stock drops after hours as bitcoin slides; Armstrong keeps crypto bill push alive in Davos

Coinbase shares fell 5.5% to $227.73 in after-hours trading Tuesday after bitcoin dropped 4.6% to about $88,312. CEO Brian Armstrong, speaking in Davos, said he remains optimistic about U.S. crypto legislation despite recent setbacks. Bermuda announced plans for a fully onchain national economy using Circle and Coinbase infrastructure, drawing regulatory attention.
21 January 2026
·····
Lam Research stock swings on tariff jitters as UBS lifts target ahead of earnings

Lam Research stock swings on tariff jitters as UBS lifts target ahead of earnings

Lam Research shares closed down 0.25% Tuesday, holding near $222 in muted after-hours trading as tariff threats from President Trump pressured tech stocks. UBS raised its price target on Lam to $255, citing strong Q2 prospects. Lam’s earnings report is set for Jan. 28. Applied Materials and KLA fell more sharply, dropping 2.7% and 5.2% respectively.
21 January 2026
····
Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly shares closed up 0.3% at $1,041.29 Tuesday and rose slightly after hours after the FDA granted Breakthrough Therapy status to its ovarian cancer drug candidate, sofetabart mipitecan. The designation targets adults with platinum-resistant ovarian cancer. Analyst Seamus Fernandez maintained a buy rating but trimmed his price target. Abivax’s CEO denied rumors of takeover talks with Lilly.
21 January 2026
·
Bloom Energy stock price swings after-hours as RBC flags Texas data-center permit

Bloom Energy stock price swings after-hours as RBC flags Texas data-center permit

Bloom Energy shares rose 1.5% to $151.75 in after-hours trading Tuesday after RBC reaffirmed its Outperform rating and $143 price target, citing an air-permit filing for a 1.5-gigawatt Texas data center project. Bloom also released a survey showing increased demand for onsite power at data centers. The stock swung between $138.68 and $155.03 during the session.
21 January 2026
···
Salesforce stock (CRM) slides after hours as Trump tariff threat hits tech — what’s next

Salesforce stock (CRM) slides after hours as Trump tariff threat hits tech — what’s next

Salesforce shares fell 3.1% to near $220 in after-hours trading Tuesday, extending an eight-session slide. The drop followed a broad tech selloff after President Trump renewed tariff threats tied to Greenland, sending the Dow down 1.76%. Trading volume for Salesforce hit 13 million shares, well above average. The stock now trades nearly 40% below its January 2025 peak.
21 January 2026
··
Costco stock price steadies after hours as tariff threat rattles markets

Costco stock price steadies after hours as tariff threat rattles markets

Costco shares edged up 0.1% to $964.26 in after-hours trading Tuesday, holding steady as Wall Street posted its sharpest drop in three months after a new U.S. tariff threat on Europe. Directors Susan L. Decker and Gina Marie Raimondo disclosed minor insider transactions. December net sales rose 8.5% to $29.86 billion. Costco will pay a $1.30 dividend on Feb. 13 and report Q2 results March 5.
21 January 2026
·
Johnson & Johnson stock price slips after-hours ahead of earnings as tariff fears rattle markets

Johnson & Johnson stock price slips after-hours ahead of earnings as tariff fears rattle markets

Johnson & Johnson shares slipped 0.2% to $218.21 in after-hours trading Tuesday ahead of quarterly earnings due Wednesday. The move followed a broad market selloff, with the Dow down 1.76% and the S&P 500 off 2.06% after new U.S. tariff threats. Analysts expect Q4 profit of $2.47 per share. The company faces ongoing litigation, including a $1.5 billion verdict over talc products.
21 January 2026
··
1 … 655 656 657 658 659 … 1,600

Stock Market Today

  • Fluor's Russell Index Additions and Pharma Feasibility Studies Could Shift Investment Outlook
    June 29, 2026, 12:41 AM EDT. Fluor Corporation (NYSE: FLR) was added to multiple Russell growth indexes in June 2026, boosting its visibility in key equity benchmarks. Concurrently, it began feasibility studies for Voyageur Pharmaceuticals on an iodine project linked to Bayer and a new contrast media manufacturing facility in North America. These moves might broaden Fluor's market exposure beyond its traditional engineering and construction segments. While the developments support Fluor's backlog and diversification story, analysts caution the near-term focus remains on managing execution risks and cash flow volatility. Fluor projects $18.3 billion revenue and $443.4 million earnings by 2029, requiring steady growth amid potential cost and labor challenges. Investor opinions vary, with some seeing upside potential beyond current valuations, while others stress caution due to operational risks.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop